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Background: Women with bilateral abnormal uterine artery Doppler velocimetry (UtADV) are at increased risk for
an adverse pregnancy outcome. This study aimed to determine if additional assessment of midtrimester angiogenic
factors improves the predictive accuracy of Doppler results for various outcome parameters.
Methods: Women with a bilateral abnormal UtADV, which was defined as a postsystolic incision and/or an
increased pulsatility index greater than the 95th centile, and a singleton pregnancy were prospectively recruited
between 19 + 0 and 26 + 6 weeks of gestation. Maternal serum levels of placental growth factor (PlGF) and soluble
fms-like tyrosine kinase-1 (sFLT-1) were measured with a fully automated immunoassay and their ratio was calculated.
Results: Angiogenic factors could predict the development of preeclampsia (PE), as well as induced delivery
at <34 weeks of gestation, but failed to predict the development of normotensive intrauterine growth restriction.
Twelve (24.0%) of the 50 recruited women developed PE. Nine of these patients had early-onset disease (<34 +
0 weeks). Six (12.0%) patients were delivered at <34 + 0 weeks. The most useful test results in the prediction of PE
and induced delivery at <34 + 0 weeks were observed using the sFLT-1/PlGF >95th centile ratio with a sensitivity,
specificity, positive predictive value, and negative predictive value (NPV) of 66.7%, 89.5%, 66.7%, and 89.5% for PE,
and 85.7%, 86.1%, 50.1%, and 97.4% for induced delivery, respectively. Positive and negative likelihood ratios were
6.33 (95% CI 2.31–17.38) and 0.37 (95% CI 0.17–0.84) for PE, and 6.14 (95% CI 2.76–13.69) and 0.17 (0.03–1.02) for
induced delivery, respectively. Corresponding odds ratios were 17.0 (95% CI 3.5–83.0) and 37.0 (95% CI 3.8–363.9),
respectively.
Conclusions: Measurement of angiogenic factors improves the specificity of an abnormal UtADV for prediction
of PE. Compared with prediction of PE an abnormal sFLT-1/PlGF ratio revealed higher sensitivity for prediction of
induced delivery at <34 + 0 weeks. The NPV of 97% will help to reassure most patients with an abnormal UtADV
and a normal sFLT-1/PlGF ratio.
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The estimated incidence of preeclampsia (PE) is between
0.4–2.8% of all pregnancies in Europe [1,2]. Only 15–20%
of PE is present a severe clinical course [3]. The majority
of severe PE develops early in pregnancy (<34 weeks of
gestation) and is frequently associated with a serious ma-
ternal and foetal outcome [4-6].
Angiogenic factors have a large effect on development
of preeclamptic syndrome [7]. The extent of the antiangio-
genic shift, characterized by an increase in antiangiogenic
soluble fms-like tyrosine kinase (sFlt)-1 and a decrease in
angiogenic placental growth factor (PlGF), correlates with
disease severity and precedes the clinical manifestation
for several weeks [8-11]. Therefore, analysis of maternal
sFLT-1 and PlGF can improve the diagnostic accuracy for
detection of PE and allows an estimation of the clinical
disease severity [12]. Moreover, removal of sFLT-1 from
the maternal circulation by apheresis improves the seve-
rity of the disease and consequently prolongs the duration
of pregnancy [13].
Although definitive treatment of PE is possible by de-
livery of the placenta alone, early prediction of high-risk
patients may enhance the patient´s care before disease
manifestation and could help to reduce mortality and
morbidity of the mother and her foetus. A widely used
noninvasive approach for identifying high-risk patients
comprises the performance of midtrimester Doppler ultra-
sound measurements of the uterine arteries. An abnormal
uterine artery Doppler velocimetry (UtADV) during the
second trimester has shown detection rates for PE be-
tween 40% and 80% in patients at low risk [14]. Generally,
sensitivity is better for the detection of severe and/or
early-onset PE compared to mild and late onset cases, but
positive predictive accuracy is quite low, and the majority
of patients with an abnormal UtADV will not develop PE
[15]. However, additional analysis of angiogenic markers
may improve the test accuracy for detecting PE. Our pro-
spective study aimed to evaluate sFLT-1 and PlGF as pre-
dictive markers for PE in a high-risk collective as identified
by an abnormal UtADV in the second trimester.
Methods
Selection and inclusion criteria of patients
Patients with a bilateral abnormal UtADV between 19 + 0
and 26 + 6 weeks of gestation were included in this pro-
spective cohort study. The clinical trial was conducted at
the Department for Obstetrics and Gynaecology of the
University of Rostock, Germany in cooperation with the
outpatient centre of prenatal diagnosis “Praxiszentrum
Frauenheilkunde” in Rostock between February 2011 and
July 2013. The study was approved by the institutional
review board of the University of Rostock (IRB No.
A2010100) and written informed consent was obtained
from all participating patients. An abnormal UtADVwas assumed if a bilaterally increased pulsatility index
(PI) greater than the 95th centile and/or a distinct postsysto-
lic incision (“notch”) were detected [16]. All measurements
were performed by two experienced observers following
the recommendations for Doppler ultrasonography mea-
surements in obstetrics [17]. For ultrasound examinations,
the Voluson 730, Voluson G8 (both GE Medical Systems,
Milwaukee, WI, USA), and HDI5000 SonoCT (Philips
Medical Systems, Bothell, WA, USA) were used. Gesta-
tional age was calculated from the first day of the last
menstrual period and was corrected by ultrasound if
measurements of the crown-rump-length during the
first trimester revealed a difference of more than 7 days.
PE was defined as being present when blood pressure
was ≥140/90 mmHg (taken twice, 6 h apart) combined
with proteinuria ≥300 mg in a 24-h collection [18]. In-
clusion of patients with chronic hypertension (blood
pressure level ≥140/90 mmHg prior to 20 weeks of
gestation) was possible. In these cases, new onset of
proteinuria ≥300 mg per day was regarded as superim-
posed PE. According to the clinical manifestation, PE
was assigned to early onset (<34 weeks of gestation) or
late onset (≥34 weeks) [19]. Haemolysis, elevated liver
enzymes, and low platelets (HELLP) syndrome was de-
fined as being present, when the platelet count was less
than 100 × 109/L (normal range: 150–450 × 109/L),
haptoglobin serum levels were below 0.3 g/L (normal
range: 0.3–2.0 g/L), and aspartate transaminase (AST)
levels were >70 U/L (normal range: 3–34 U/L). Only
singleton pregnancies were included. Exclusion criteria
were maternal age <18 years, on-going therapy with
glucocorticoids or non-steroidal analgesics (with ex-
ception of aspirin 100 mg daily), and the presence of
anti-phospholipid syndrome.
Small for gestational age (SGA) was defined as a birth
weight less than the 10th centile for gestational age ac-
cording to Voigt et al. [20]. Intrauterine growth restric-
tion (IUGR) was assumed when a SGA birth weight was
combined with at least one of the following criteria: (1)
oligohydramnios with an amniotic fluid index <5 cm, (2)
persistent bilateral abnormal UtADV, (3) a pathological
cardiogram, (4) a decrease in foetal growth by ultra-
sound biometry (“crossing centiles”), and (5) increased
PI of the umbilical artery greater than the 95th centile.
Because clinicians were not aware of biomarker results,
an effect of decision making for the obstetric approach
was excluded.
Sample collection and immunoassays
From each study patient, 2 × 7.5 mL of venous blood
was taken at the time of Doppler measurement using a
serum collection tube (Sarstedt, Nümbrecht, Germany).
The blood clot was immediately separated by centrifuga-
tion at 2000 × g for 10 min at 15°C and serum was stored
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performed. Serum concentrations of PlGF and sFLT-1
were measured with the fully automated Elecsys® sandwich
immunoassays (Roche Diagnostics, Penzberg, Germany)
based on streptavidin-biotin technology. The assays were
performed using the Roche immunoanalyser Elecsys® 2010/
cobas e 411 according to the recommendations of the
manufacturer. Within and between run coefficients of
variation were below 4% for sFLT-1 > 60 pg/mL and
PlGF >20 pg/mL. Functional sensitivity was <5 pg/mL
[21,22]. Results were classified using gestational age-
dependent centile curves that were provided by the
manufacturer and based on data from Verlohren and
colleagues [10]. Results were regarded as pathological if
sFLT-1 or the ratio of sFLT-1/PlGF was greater than the
95th centile and/or PlGF was less than the 5th centile.
Statistical analysis
All data were stored and analysed using the IBM SPSS
statistical package 19.0 (SPSS Inc. Chicago, IL, USA) and
Excel 2010 (Microsoft Corporation, Redmond, WA,
USA). Descriptive statistics were computed for continu-
ous and categorical variables. The statistics included
mean, median, standard deviation (SD), minimum, max-
imum, and number of available observations of continu-
ous variables. Values of continuous variables are presented
as mean ± SD. For categorical variables, frequencies and
relative frequencies are shown. Testing for differences of
continuous variables between the groups was accom-
plished by the ANOVA or the Kruskal–Wallis test, as ap-
propriate. Test selection was based on evaluation of the
variables for normal distribution by using the Kolmogo-
rov–Smirnov test. Comparison between the groups for
categorical variables was performed using the chi-square
test. All P values resulted from two-sided statistical tests
and values of P < 0.05 were considered as statistically sig-
nificant. Criteria of diagnostic validity for sFLT-1 and PlGF
alone, as well as the sFLT-1/PlGF ratio, were computed
and presented as sensitivity, specificity, positive predictive
value (PPV), negative predictive value (NPV), positive like-
lihood ratio, and negative likelihood ratio. Furthermore,
receiver operating characteristic (ROC) curves were calcu-
lated and the areas under the curves (AUCs) were re-
ported. The most useful cut-off values were calculated by
identification of the highest score for sensitivity and speci-
ficity. For the sFLT-1/PlGF ratio >95th centile, odds ratios
(OR) were computed for various outcome parameters.
The logistic regression model was used to assess the inde-
pendence of specific outcome parameters. Variables yield-
ing P values ≤0.05 in univariate analysis were entered in the
multivariate model and adjusted for maternal body mass
index, parity, onset of PE, existence of chronic hyperten-
sion, week of gestation at the moment of blood sampling,
and use of acetylsalicylic acid. We performed post hocanalysis for estimation of the statistical power of our
study collective by logistic regression analysis using
G*Power 3.1.9.2 [23]. One-tailed power analysis for pre-
diction of PE by the sFLT-1/PlGF ratio with an α error




The patients’ characteristics are shown in Table 1 with
the following prevalence of subgroups: PE was found in
24.0% (12/50) of patients, IUGR in 12.0% (6/50), gesta-
tional hypertension in 32.0% (16/50), and others in
32.0% (16/50). Subgroup analysis did not show any dif-
ferences between maternal characteristics, such as age,
gravidity, parity, and body mass index. In contrast, sig-
nificant intergroup differences were found regarding
foetal/neonatal parameters. More than 40% of all pre-
eclamptic newborns showed a SGA birth weight. New-
borns in the PE subgroup also presented with the lowest
mean gestational age. Consequently, the mean birth
weight in cases of PE was significantly lower compared
with that in the other subgroups, including newborns
with normotensive IUGR. Delivery at <34 + 0 weeks oc-
curred in 14.0% (7/50) of all patients. Five of them
(71.4%) had PE and two had severe hypertension without
proteinuria. All of these patients had an induced delivery
because of a severe clinical course indicated by the phy-
sicians on duty. One patient with chronic hypertension
and concomitant diabetes mellitus type II had an intra-
uterine foetal death at 26 weeks of gestation. Induction of
lung maturation with betamethasone was not performed
in three newborns with induced delivery at <34 + 0 weeks,
including the patient with intrauterine foetal death. Dop-
pler measurements were repeated in all of the patients
after 4 weeks. An abnormal UtADV normalized in 32.0%
(16/50) of all cases. There were significant differences be-
tween subgroups (P = 0.047) with normalization of an ab-
normal uterine Doppler in 0.0% of PE (0/12), 33.3% of
IUGR (2/6), 31.3% of gestational hypertension (5/16), and
56.3% in the remaining patients (9/16).
Prediction of PE by UtADV, PlGF, sFLT-1, and the sFLT-1/
PlGF ratio
The prevalence of PE in our high-risk study collective
was 24.0% (12/50), with 75.0% (9/12) early-onset and
25.0% (3/12) late-onset diseases. PE was also present
with chronic hypertension in four cases (all early onset).
One patient developed concomitant HELLP syndrome.
For prediction of PE, bilateral UtADV showed a PPV of
only 24.0% with a false-positive rate (FPR) of 76.0%. Per-
formance of ROC analysis using the mean PI of the uterine
arteries showed an AUC of 0.630. At the optimal cut-off
with a mean uterine PI ≥1.86, the specificity increased to
Table 1 Maternal and foetal characteristics of the study population
Characteristic All patients (n = 50) PE (n = 12) IUGR (n = 6)# GH (n = 16) Others (n = 16) P-value
Age, y
Mean ± SD 29.7 ± 4.9 29.8 ± 3.9 33.3 ± 4.8 28.3 ± 3.6 29.6 ± 6.3 0.206*
Minimum - maximum 19 - 40 24 - 38 28 - 40 22 - 34 19 - 39
Gravidity 0.613**
Median 1 1 2 1 2
Minimum - maximum 1 - 9 1 - 9 1 - 8 1 - 5 1 - 5
Parity 0.612**
Median 0 0 0 0 0
Minimum - maximum 0 - 5 0 - 4 0 - 5 0 - 2 0 - 1
Body mass index (pregravid), kg/m2 0.132*
Mean ± SD 27.1 ± 8.2 30.6 ± 8.0 21.7 ± 3.2 28.1 ± 9.1 25.6 ± 6.3
Minimum - maximum 14.5 - 47.0 19.8 - 45.0 18.7 - 27.3 14.5 - 45.7 18.8 - 47.0
Chronic hypertension, n (%) 8 (16.0%) 4 (33.3%) 0 (0.0%) 4 (25.0%) 0 (0.0%) 0.049***
Thrombophilia, n (%) 5 (10.0%) 0 (0.0%) 0 (0.0%) 3 (18.8%) 2 (12.5%) 0.755***
Nicotine abuse, n (%) 14 (28.0%) 5 (41.7%) 1 (16.7%) 6 (37.5%) 2 (12.5%) 0.238***
Highest systolic blood pressure, mmHg < 0.001*
Mean ± SD 143.2 ± 23.1 165.8 ± 21.2 128.7 ± 5.4 149.4 ± 20.0 124.7 ± 9.9
Minimum - maximum 110 - 200 140 - 200 120 - 135 130 - 200 110 - 140
Highest diastolic blood pressure, mmHg < 0.001*
Mean ± SD 90.4 ± 17.6 110.5 ± 13.4 79.7 ± 6.2 91.8 ± 15.9 77.3 ± 7.1
Minimum - maximum 60 - 130 90 - 130 70 - 86 60 - 124 60 - 90
Proteinuria, mg/d
Mean ± SD 1180 ± 2524 2613 ± 3394 n.a. 157 ± 196 n.a.
Minimum - maximum 0 - 9986 109 - 9986 n.a. 0 - 283 n.a.
Placenta weight, g 0.129*
Mean ± SD 324 ± 98 300 ± 86 322 ± 29 286 ± 145 443 ± 71
Minimum - maximum 124 - 510 182 - 461 283 - 364 124 - 476 369 - 510
Amnion fluid index (AFI), n (%) 0.839***
Oligohydramnion (AFI≤ 8) 13 (26.0%) 3 (25.0%) 2 (33.3%) 4 (25.0%) 4 (25.0%)
Polyhydramnion (AFI > 18) 7 (14.0%) 3 (25.0%) 1 (16.7%) 1 (6.3%) 2 (12.5%)
Birth weight, g < 0.001*
Mean ± SD 2588 ± 809 1859 ± 658 2270 ± 303 2588 ± 750 3175 ± 626
Minimum - maximum 620 - 3940 890 - 2980 1750 - 2620 620 - 3610 1860 - 3940
Percentile of birth weight, n (%)
SGA (<10th centile) 16 (32.0%) 5 (41.7%) 6 (100.0%) 6 (37.5%) 0 (0.0%)
LGA (>90th centile) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
5´-APGAR-Score 0.398**
Median 10 9 10 10 10
Minimum - maximum 8 - 10 8 - 10 9 - 10 8 - 10 9 - 10
Induction of lung maturation, n (%) 13 (26.0%) 4 (33.3%) 6 (100.0%) 2 (12.5%) 1 (6.3%) 0.019***
Stubert et al. BMC Pregnancy and Childbirth 2014, 14:292 Page 4 of 11
http://www.biomedcentral.com/1471-2393/14/292
Table 1 Maternal and foetal characteristics of the study population (Continued)
Newborns < 34 + 0 weeks, n (%) 7 (14.0%) 5 (41.7%) 0 (0.0%) 2 (12.5%) 0 (0.0%) 0.008***
Gestational age at delivery, weeks + days 0.009**
Mean (w + d) ± SD (d) 37 + 2 ± 24 34 + 4 ± 26 37 + 5 ± 5 37 + 4 ± 25 38 + 6 ± 17
Minimum - maximum 26 + 4 - 42 + 0 27 + 4 - 40 + 3 36 + 5 - 39 + 0 26 + 2 – 41 + 0 34 + 1 - 42 + 0
# normotensive IUGR only.
* = ANOVA.
** = Kruskal–Wallis test.
*** = Chi-Square test.
n.a. = not available, PE = Preeclampsia, GH = Gestational hypertension, IUGR = Intrauterine growth restriction, SGA = Small for gestational age, LGA = Large for
gestational age.
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rate also increased to 45.5%, resulting in a predictive
accuracy of only 70.0%. In contrast, serum levels of
PlGF and sFLT-1, as well as the sFLT-1/PlGF ratio,
clearly improved discrimination between patients with
and without PE (Figure 1, Table 2). If values were
greater than the 95th centile of gestation, the sFLT-1/
PlGF ratio showed most useful test characteristics for
PE, with a sensitivity of 66.7% and an FPR of only
10.5% (Table 3). The corresponding PPV was 66.7%,
with an NPV of 89.5% and a predictive accuracy of the
ratio of 84.0%. An elevated sFLT-1/PlGF ratio greater
than the 95th centile was associated with an increased
risk for development of PE (OR 17.0; 95% confidence
interval [CI] 3.5–83.0, P < 0.001) (Table 3). Results
remained significant after weighting of parameters in
multiple regression analysis with an adjusted OR for PE
(adjusted OR 14.1; 95% CI 1.1–182.6, P = 0.043).
The sensitivity increased to 75.0% if only early-onset PE
was included, but FPR also increased to 14.3%. We found
four false-positive cases, where one patient showed a
normotensive IUGR and two had hypertension without
proteinuria (one with concomitant IUGR and one with
intrauterine foetal death at 26 weeks of gestation). Two
out of the four false-negative patients developed early-
onset PE (one patient with concomitant HELLP syndrome
at <34 weeks of gestation) and two developed late-onset
PE (with only a mild clinical course in one patient). TheFigure 1 Prediction of PE. Boxplot analysis of maternal serum PlGF (A) and
preeclampsia (PE, n = 12) were compared with all patients without PE (n = 38
(top and bottom lines of the box). The lines outside the box represent minim
range). P values were computed by Mann–Whitney statistical tests.fourth patient with false-negative serum markers devel-
oped late-onset PE, but fulfilled the criteria of severity
with hypertension >160/110 mmHg. ROC analysis showed
an AUC of 0.721 for the sFLT-1/PlGF ratio, with the best
predictive cut-off of 13.0, resulting in a sensitivity of 66.7%
with an FPR of 13.2% (Figure 2, Table 4). If a fixed FPR of
10% was assumed, the cut-off level of the ratio changed to
22.4, with a sensitivity of only 41.7%.
Prediction of hypertension without proteinuria, IUGR, and
induced delivery at <34 weeks of gestation
Results were further analysed in respect to development of
hypertension without proteinuria and IUGR. As shown in
Table 2, serum levels of PlGF were significantly lower in
cases of IUGR compared to uncomplicated controls (P =
0.033), but failed significance if used as predictive param-
eter throughout the whole study population (Table 3).
However, we found significant differences of the angiogenic
markers if results were analysed in relation to gestational
age at delivery (Figure 3). Measurements of sFLT-1 and
PlGF were useful predictive markers for delivery at <34 +
0 weeks of gestation. If ROC analysis was performed, the
AUC for the sFLT-1/PlGF ratio was 0.877, with a best cut-
off of 13.0 (Figure 2). This cut-off resulted in a sensitivity
of 85.7% with an FPR of 16.3%. If gestational age-
dependent threshold levels greater than the 95th centile
were used, the FPR improved to 13.9% with the same
sensitivity. The PPV and NPV were 50.1% and 97.4%,sFLT-1 (B) levels and their ratio (C). Patients with development of
). Boxes show the median (black line), and 25th, and 75th percentiles
um and maximum values. Circles are outliers (>1.5× from the interquartile
Table 2 Maternal serum PlGF and sFLT-1 levels and their ratio
PE (n = 12) No PE (n = 38) P-valuea Others (n = 16)
(Uncomplicated)
GH (n = 16) P-valueb Normotensive
IUGR (n = 6)
P-valuec Delivery < 34
weeks (n = 7)
Delivery ≥ 34
weeks (n = 44)
P-valued




0.033 75.1 (64.6-131.7) 221.7
(117.4-336.4)
0.003











sFLT-1/PlGF ratio 18.8 (4.8-29.1) 6.2 (3.4-8.8) 0.022 5.9 (2.9-8.6) 5.9 (3.6-9.1) 0.366 8.6 (4.0-19.6) 0.161 29.4 (14.1-53.9) 6.0 (3.4-9.0) 0.001
Data are given as median (interquartile range).
a Mann–Whitney statistical test comparing PE vs No PE.
b Mann–Whitney statistical test comparing GH vs Others.
c Mann–Whitney statistical test comparing IUGR vs Others.
d Mann–Whitney statistical test comparing delivery < 34 weeks vs delivery ≥ 34 weeks.



















Table 3 Diagnostic indices of maternal PlGF, sFLT-1, and their ratio for identifying patients who will develop
preeclampsia, hypertension without proteinuria, normotensive IUGR, and induced delivery at <34 weeks of gestation
Chi-Square
P-value
Sensitivity Specificity PPV NPV LR + (95% CI) LR- (95% CI) OR (95% CI)
PE (n = 12) PlGF 0.027 58.3% 78.9% 46.7% 85.7% 2.77 (1.27-6.04) 0.53 (0.27-1.05) 5.25 (1.31-21.03)
sFLT-1 0.240 16.7% 94.7% 50.0% 78.3% 3.17 (0.50-20.13) 0.88 (0.68-1.15) 3.60 (0.45-28.86)




PlGF 0.514 37.5% 73.5% 40.0% 71.4% 1.42 (0.61-3.30) 0.85 (0.55-1.31) 1.67 (0.47-5.92)
sFLT-1 1.000 6.3% 91.2% 25.0% 67.4% 0.71 (0.08-6.29) 1.03 (0.87-1.21) 0.69 (0.067-7.19)
sFLT-1/PlGF ratio 0.292 12.5% 70.6% 16.7% 63.2% 0.43 (0.11-1.72) 1.24 (0.93-1.65) 0.34 (0.07-1.79)
IUGR (n = 6) PlGF 0.654 16.7% 68.2% 6.7% 85.7% 0.52 (0.08-3.30) 1.22 (0.81-1.84) 0.43 (0.05-4.02)
sFLT-1 1.000 0.0% 90.9% 0.0% 87.0% 0.00 1.10 (1.00-1.21) 0.00
sFLT-1/PlGF ratio 1.000 16.7% 75.0% 8.3% 86.8% 0.67 (0.10-4.29) 1.11 (0.75-1.65) 0.60 (0.06-5.71)
Induced delivery
< 34 weeks (n = 7)
PlGF 0.176 57.1% 74.4% 26.7% 91.4% 2.23 (0.98-5.07) 0.58 (0.34-1.38) 3.88 (0.75-20.12)
sFLT-1 0.089 28.6% 95.4% 50.3% 89.1% 6.14 (1.03-36.79) 0.75 (0.47-1.20) 8.20 (0.94-71.73)
sFLT-1/PlGF ratio <0.001 85.7% 86.1% 50.1% 97.4% 6.14 (2.76-13.69) 0.17 (0.03-1.02) 37.00 (3.76-363.91)
Early-onset
PE (n = 9)
PlGF 0.220 50.0% 73.8% 26.7% 88.6% 1.91 (0.81-4.51) 0.68 (0.33-1.39) 2.82 (0.60-13.24)
sFLT-1 0.115 25.0% 95.2% 50.0% 87.0% 5.25 (0.86-32.02) 0.79 (0.53-1.18) 6.67 (0.79-56.64)
sFLT-1/PlGF ratio 0.001 75.0% 85.7% 50.0% 94.7% 5.25 (2.26-12.18) 0.29 (0.09-0.98) 18.00 (2.92-110.96)
Late-onset
PE (n = 3)
PlGF 0.075 75.0% 73.9% 20.0% 97.1% 2.88 (1.36-6.06) 0.34 (0.06-1.86) 8.50 (0.81-89.75)
sFLT-1 1.000 0.0% 91.3% 0.0% 91.3% 0.00 1.10 (1.00-1.20) 0.00
sFLT-1/PlGF ratio 0.240 50.0% 78.3% 16.7% 94.7% 2.30 (0.75-7.07) 0.64 (0.24-1.72) 3.60 (0.46-28.86)
Cut-off levels were defined as < 5th centile for PlGF and > 95th centile for sFLT-1 and the sFLT-1/PlGF ratio according to gestational specific reference values.
PE = Preeclampsia, GH = Gestational hypertension, IUGR = Intrauterine growth restriction, PPV = Positive predictive value, NPV = Negative predictive value,
OR = Odds ratio, LR+/− = positive/negative Likelihood ratio.
Figure 2 ROC curves for prediction of PE (A) and induced delivery at <34 weeks of gestation (B) by using the sFLT-1/PlGF ratio.
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Table 4 Results of receiver operating characteristic curve analysis with AUC values and cut-off levels of maternal serum
PlGF (pg/mL) and sFLT-1 (pg/mL) levels and their ratio, resulting in optimal sensitivity and specificity
AUC Cut-off Sensitivity Specificity PPV NPV
PE (n = 12) PlGF 0.697 133.8 75.0% 76.3% 50.0% 90.6%
sFLT-1 0.693 1171.5 91.7% 52.6% 37.9% 95.3%
sFLT-1/PlGF ratio 0.721 13.0 66.7% 86.8% 61.5% 89.2%
EO PE (n = 9) sFLT-1/PlGF ratio 0.735 13.0 75.0% 83.3% 51.4% 93.4%
Gestational hypertension (n = 16) PlGF 0.494 117.6 37.5% 70.6% 37.5% 70.6%
sFLT-1 0.364 590.5 100.0% 11.8% 34.8% 100.0%
sFLT-1/PlGF ratio 0.456 2.3 100.0% 8.8% 34.0% 100.0%
IUGR (n = 6) PlGF 0.640 262.3 100.0% 38.6% 18.2% 100.0%
sFLT-1 0.439 1751.0 50.0% 63.6% 15.8% 90.3%
sFLT-1/PlGF ratio 0.564 8.0 66.7% 56.8% 17.4% 92.6%
Induced delivery < 34 weeks (n = 7) PlGF 0.834 133.8 85.7% 72.1% 33.3% 96.9%
sFLT-1 0.807 1850.5 85.7% 74.4% 35.3% 97.0%
sFLT-1/PlGF ratio 0.877 13.0 85.7% 83.7% 46.1% 97.3%
PE = Preeclampsia, EO = Early-onset, IUGR = Intrauterine growth restriction, ID = Induced delivery, PPV = positive predictive value, NPV = negative predictive value.
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accuracy of 86.0%. An elevated sFLT-1/PlGF ratio greater
than the 95th centile was associated with an increased risk
for delivery at <34 + 0 weeks (OR 37.0; 95% CI 3.8–363.9,
P < 0.001) (Table 3). Results remained significant after
weighting of parameters in multiple regression analysis with
an adjusted OR (34.6; 95% CI 1.2–1026.2, P = 0.041).
Discussion
Main findings
Patients with an abnormal UtADV showed distinct foetal
and maternal morbidity, with a high prevalence of PE,
IUGR, and hypertensive disorders without proteinuria.
However, only one of four patients with abnormal UtADV
developed PE. Additional measurement of the sFLT-1/
PlGF ratio was able to decrease the FPR from 76.0% to
10.5%. A negative test result below the 95th gestational
age-specific centile showed an NPV of 89.5%. The NPV
was further improved if only patients with early onset PE
(94.7%) or those who required delivery at <34 weeksFigure 3 Prediction of preterm delivery < 34 weeks. Boxplot analysis
(C). Patients with delivery at <34 weeks of gestation (n = 6) were compared
line), and 25th and 75th percentiles (top and bottom lines of the box). The
are outliers (>1.5× from the interquartile range). P values were computed b(97.4%) were considered. Therefore, women with a normal
sFLT-1/PlGF ratio were at low risk for development of
one of these severe clinical courses. Additional measure-
ment of sFLT-1 and PlGF would be helpful to reassure the
majority of patients with an abnormal UtADV. An in-
creased angiogenic ratio was associated with an increased
risk of a severe hypertensive disorder and concomitant
preterm delivery. Provident corticosteroid treatment of
these women should be considered.
Interpretation
There are different approaches for prediction of PE.
Doppler ultrasound of the uterine arteries during the
second trimester is the best-known single predictor for
PE, with a detection rate up to 80% for early-onset dis-
ease [14,24-26]. However, the majority of patients with
abnormal UtADV will never develop PE, which suggests
the need to improve the predictive accuracy. Therefore,
use of a well-established and widely performed test for
identification of a high risk collective and its combinationof maternal serum PlGF (A) and sFLT-1 (B) levels and their ratio
with the remaining patients (n = 44). Boxes show the median (black
lines outside the box represent minimum and maximum values. Circles
y Mann–Whitney statistical tests.
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of specificity is a practically oriented approach. The use of
a fully automated diagnostic system that analyses sFLT-
1 and PlGF guarantees a high test quality. The Elecsys®
immunoassays show high precision and reliability, and
allow execution of measurements in laboratories for
routine clinical diagnosis [21].
Recent studies have reported complex algorithms that
allow prediction of PE by integration of miscellaneous
risk factors, including analysis of angiogenic factors be-
tween 11–13 weeks of gestation [27-29]. Identification of
high-risk patients during the first trimester offers the
advantage of a preventive therapy with low-dose aspirin,
which more than halves the risk of severe PE [30]. How-
ever, the ability of prediction or exclusion of PE during
the second trimester may also be useful because it can
facilitate decision making as to whether intensified pa-
tient’s care or corticosteroid treatment for foetal lung
maturation will be necessary. There is also increasing
evidence for effective preventive treatment strategies in
high-risk patients during the second trimester [31-33].
Various (nested) case–control studies have examined the
differences in maternal angiogenic protein concentra-
tions during the second trimester preceding the occur-
rence of PE [8,34-41]. The usefulness of circulating
sFLT-1 and PlGF as a test to predict PE in healthy preg-
nant women was recently proven in a comprehensive
prospective cohort study by McElrath and colleagues
[11]. In a cohort of 2243 patients, the plasma levels of
angiogenic factors were repeatedly measured at 10, 17,
24, and 35 weeks of gestation. In the study sample, 139
(6.2%) patients developed PE. At 10 weeks of gestation,
the authors did not find any significant differences be-
tween plasma concentrations of PlGF or sFLT-1, or the
sFLT-1/PIGF ratio in patients with PE compared with
healthy controls. Differences became significant at
17 weeks for PlGF (P = 0.009) alone, and were highly sig-
nificant for PlGF and the sFLT-1/PIGF ratio at 24 weeks
(P < 0.001). In contrast, differences for sFLT-1 became
significant at 35 weeks. At 24 weeks, the highest detec-
tion rate (62.2%) was observed for PlGF alone, with an
FPR of 38.4% and a PPV of 9.5%. The relative risk for
development of PE was 2.46 (95% CI 1.66–-3.65) if a
cut-off level of 379 pg/mL was used [11]. Similar results
were shown in a further prospective study including
1622 healthy Hispanic women [25]. Maternal plasma
concentrations of various angiogenic proteins were mea-
sured at 6–15 and 20–25 weeks of gestation. During
pregnancy, 3.8% of patients developed PE (n = 62), and
0.6% had early-onset PE (n = 9). In midtrimester, PlGF
measurements alone showed a better test performance
(P < 0.001) than sFLT-1 (P = 0.5) or the sFLT-1/PIGF ra-
tio (P = 0.006). However, the detection rate for PlGF was
only 51.6%, with an FPR of 23.6% and a PPV of 8%. Areasonable cut-off value was 215 pg/mL, resulting in an
OR of 3.8 (95% CI 2.2–6.7). The detection rate for early-
onset PE was 100%, and was therefore better, with an
FPR of only 4.2% at a cut-off level of 126 pg/mL [25].
The authors of both studies concluded that angiogenic
protein concentrations alone, measured in early or even
late pregnancy, were of limited utility for prediction of
PE. For prediction of PE, its low incidence and concomi-
tant low predictive value are problematic. Therefore,
identification of high-risk patients may be an alternative,
more suitable approach. In a prospective cohort study of
3348 patients, Espinoza and colleagues examined the re-
lationship between UtADV and plasma concentrations
of PlGF and sFLT-1 between 22 and 26 weeks of gesta-
tion [24]. In this study, they showed that abnormal
UtADV and maternal PlGF were independent explana-
tory variables for the occurrence of PE. For prediction of
PE, the FPR of abnormal UtADV alone was low (10.4%).
Abnormal UtADV had a better test performance than
maternal PlGF for identification of a high-risk collective,
with ORs for all types of PE and early-onset PE of 4.3
(95% CI 2.82–6.66) and 24.1 (95% CI 9.61–60.44) com-
pared with PlGF (cut-off, 280 pg/mL), with correspond-
ing ORs of 2.6 (95% CI 1.57–3.94) and 5.5 (95% CI
1.98–15.08). The combination of both parameters in-
creased the OR for early-onset PE to 43.8 (95% CI
18.48–103.9). The PPV for early-onset PE was improved
from 5.4% for abnormal UtADV and 1.4% for PlGF alone
to 12.7% if both factors were combined with a positive
likelihood ratio of 18.48 (95% CI 13.07–26.13). This
study [24] impressively showed that PlGF significantly
contributed to the prediction of patients who were going
to develop early-onset PE, and thus confirmed the re-
sults of a smaller study by Stepan and colleagues [42].
The supplemental table compares the test characteristics
of the sFLT-1/PlGF ratio of various studies (Additional
file 1: Table S1). The prospective cohort study by Moore
Simas and colleagues included only patients with at least
one risk factor for PE in their medical history [43]. In
this study, the determination of sFLT-1 showed a good
predictive accuracy for early-onset PE, with an AUC
value of 0.90 (95% CI 0.78–1.0) between 22 and 26 weeks
of gestation. The sFLT-1/PlGF ratio was even better with
an AUC value of 0.97 (95% CI 0.91–1.0). Similar results
of other studies, including our own data, showed an in-
crease in specificity if the sFLT-1/PlGF ratio instead of
PlGF alone was used for prediction of early-onset PE.
However, compared with a decrease in PlGF, an increase
in sFLT-1 in patients with PE is a late event, with only a
narrow time frame between diagnosis and clinical mani-
festation of PE [8,11].
Although the end-point of our study was the develop-
ment of PE, we additionally analysed the correlation be-
tween angiogenic factors and the occurrence of other
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at <34 weeks. The group of induced deliveries showed
great overlap with the PE cases and could be regarded as
a surrogate for a severe clinical course. Therefore, iden-
tification of these patients is of high clinical relevance.
With an AUC of 0.88, we observed a satisfactory test
performance for prediction of cases with a delivery
at <34 weeks of gestation. Although PPV was only 50.1%,
we found an NPV of 97.4%. In patients with abnormal
UtADV and a normal angiogenic ratio, the need for
delivery at <34 weeks following hypertensive pregnancy
disorders is highly unlikely. With a sensitivity of 71% and
a specificity of 76%, Stepan and colleagues also reported
the capability of the sFLT-1/PlGF ratio for prediction of
preterm delivery [42]. Additionally, in a prospective study
of patients with suspected early-onset PE, the sFLT-1/
PlGF ratio showed prognostic relevance [44]. Patients with
a ratio ≥85 had a significantly increased risk for delivery
within the next 2 weeks, with a hazard ratio of 15.2 (95%
CI 8.0–28.7).
In our study, angiogenic factors were not suitable for
prediction of hypertension without proteinuria or for
normotensive IUGR, although in IUGR, the levels of PlGF
were significantly lower compared with inconspicuous con-
trols. Differences reported in other studies were also only
moderate, and not helpful for diagnosis or prediction of
these adverse pregnancy outcome parameters [12,41,42].
Conclusion
In high-risk patients, measurement of angiogenic factors
shows a good predictive power for development of PE.
The best results can be achieved using the ratio of sFLT-1
and PlGF, with a predictive test accuracy of 84%. In pa-
tients with abnormal UtADV, a high FPR of Doppler
measurement alone is improved to 10.5%. An increased
sFLT-1/PlGF ratio is also predictive for patients who need
delivery at <34 + 0 weeks of gestation. The test performed
even better for prediction of preterm delivery compared
with PE, with a sensitivity and specificity of >80%. In par-
ticular, a NPV of 97.4% can help to reassure most patients
with an abnormal UtADV.
Additional file
Additional file 1: Table S1. Test indices of the midtrimester sFlt-1/PlGF
ratio for prediction of preeclampsia. Comparison of relevant studies
(see Discussion).
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